The pace of discovery in neuromuscular research has never been faster or more vulnerable. As the global research ecosystem faces economic, regulatory, and logistical uncertainty, it is all the more critical for us to come together with purpose, urgency, and clarity.
That’s what the MDA Clinical and Scientific Conference has always done best.
This annual conference is more than a showcase of the most promising research and care models in neuromuscular disease. It is a working session among the most relentless minds in neuroscience, genetics, and translational medicine. We gather to advance, challenge, and sharpen each other’s work. We gather to ensure that progress doesn’t stall and that the momentum we’ve built continues to accelerate.
In 2026, our conference will once again bring together world-class clinicians, researchers, and industry leaders whose shared commitment to people living with neuromuscular disease rises above any single institution, funding cycle, or frontier of discovery. You’ll find leaders in muscular dystrophy, CMT, SMA and ALS alongside promising new voices investigating underexplored rare conditions. You’ll see fresh clinical trial strategies and real-world data on FDA-approved therapies presented with transparency and intent. And you’ll find every session infused with a sense of shared responsibility to patients, families, and to one another.
I hope you’ll join us in 2026, not simply to hear what’s new but to be part of what’s next.
Sincerely,
Sharon Hesterlee, PhD
interim President and CEO
Muscular Dystrophy Association